Form 4: CRISPR Therapeutics GC Receives Equity Grant

General Counsel and Secretary James R. Kasinger was granted 17,000 restricted stock units by CRISPR Therapeutics AG.

Summary

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, received a grant of 17,000 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one common share of the company.
• The grant was issued on May 29, 2026, with a zero-dollar exercise price.
• The entire award is scheduled to vest on November 29, 2028.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding executive compensation with no immediate impact on company operations or financial health.

Positives

• Equity-based compensation aligns the interests of the General Counsel with long-term shareholder value.

Negatives

• The grant results in potential future dilution for existing shareholders upon vesting.

Risks

• The value of the equity grant is subject to market volatility of CRSP common shares until the vesting date in 2028.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an executive equity grant.

Industry Context

StockSavvy.ai notes that equity grants to key executives are standard practice in the biotechnology sector to ensure retention and alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of multi-year cliff vesting for RSU grants is consistent with standard executive compensation packages in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual vesting and issuance of the underlying common shares.

Next Steps

• Vesting of the 17,000 RSUs on November 29, 2028.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Transaction, Equity Compensation, Biotech